Sonnet biotherapeutics provides fiscal year 2022 first quarter business and earnings update

Son-1010 and son-080 on track to initiate clinical studies during the second quarter of 2022 completed r&d manufacturing for son-1210 non-glp toxicity study in non-human primates, with study initiation planned for the first half of 2022 continue to advance preclinical development of fhab pipeline princeton, nj / accesswire / february 8, 2022 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) ("sonnet" or the "company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months ended december 31, 2021 and provided a business update. "throughout the quarter, we've continued to advance towards the clinic with our proprietary fully human albumin binding (fhab) pipeline assets, and our partnered product, son-080," said pankaj mohan, ph.d.
SONN Ratings Summary
SONN Quant Ranking